From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback